OncoCyte Corporation stock is up 19.29% since 30 days ago. The next earnings date is Apr 3, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 December’s closed higher than November. 50% of analysts rate it a buy.
OncoCyte Corporation researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services.